Scientific and clinical advisory board

Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and clinical research. In 2009, he won the Lily Prize of the British Pharmacology Society. Since 2008, he directs the Barts National Institute of Health Research Cardiovascular Biomedical Research Unit. He was appointed Director of the William Harvey Research Institute in 2002 and elected to the Academy of Medical Sciences in 2008, and was President of the British Hypertension Society (2009-2011). He served on the NICE Guideline Group for hypertension. Since 1996, he has been National Co-ordinator of the MRC British Genetics of Hypertension (BRIGHT) Study on behalf of 5 UK Universities. He was on the Steering Group of the Anglo-Scandinavian Cardiac Outcome Trial recruiting 1157 hypertensives.This trial has changed international guidance on lipid lowering and high blood pressure treatment. In 2007, 2009 and 2011 his research has been independently rated amongst the top ten scientific discoveries in his field.

Co-director of William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London (UK). Director of the NIHR Biomedical Research Unit in Cardiovascular Disease at Barts (UK). Member of the UK Academy of Medical Sciences.

Alexandre Persu is professor of Medicine, specialist in Hypertension and Nephrology, head of the Hypertension outpatient clinic and Chef de Clinique in Cardiology at the Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium. He is also secretary of the Belgian Hypertension Committee (BHC), member of the Editorial Board of the European Journal of Clinical Investigation and former member of the Editorial Board of the Journal of Hypertension. Currently, his main research interests are resistant and secondary hypertension.

Head of the Hypertension Clinic, Cardiology Department, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium. Member of the International and European Society of Hypertension.

Professor Toshiro Fujita is Professor of the Department of Clinical Epigenetics, RCAST, the University of Tokyo and Director, CREST, JST Strategic Basic Research Program. He qualified in medicine in 1972 at the Keio University School of Medicine in Japan. His contribution to the study of hypertension and kidney diseases has been widely recognized. In 1980, Fujita and Bartter at NIH demonstrated the pathogenesis of salt-sensitive hypertension. Dr. Fujita’s group has reported the involvement of aldosterone/mineralocorticoid receptor activation in salt-sensitive hypertension and metabolic syndrome. Professor Fujita has been actively contributing to professional associations and scientific publications. Over the past 30 years, Professor Fujita has published more than 600 scientific articles. In 2013, he was awarded ESH Honorary Membership Award, European Society of Hypertension (ESH) and the International Award of Okamoto. In 2014, he received Franz Volhard Award from the International Society of Hypertension (ISH) and the Excellence Award for Hypertension Research from the Council for Hypertension, AHA. He was President of the Japanese Society of Hypertension, the Japanese Society of Internal Medicine, the Japanese Society of Endocrinology, and the Japanese Society of Nephrology. Since 2003, he has been involved in High Blood Pressure Council (HBPR), and is currently a member of HBPR Leadership Committee.

Professor of the Department of Clinical Epigenetics, RCAST, The University of Tokyo. Former President of the Japanese Society of Hypertension. Vice-President of the International Society of Hypertension.

Keith C. Ferdinand, MD, is Professor of Medicine at the Tulane University School of Medicine in New Orleans, Louisiana. He is board-certified in internal medicine and cardiovascular disease, certified in the subspecialty of nuclear cardiology, and a specialist in clinical hypertension certified by the American Society of Hypertension. Dr. Ferdinand is Immediate Past Chair of the National Forum for Heart Disease and Stroke Prevention. As an investigator, Dr. Ferdinand has conducted numerous trials and widely published in the fields of cardiology, cardiovascular disease, hypertension, lipids and cardio metabolic risk, especially in racial and ethnic minorities. In 2015, he was the Editor of the book, “Hypertension in High Risk African Americans”, published by Springer. In 2004, Dr. Ferdinand received the Louis B. Russell, Jr. Memorial Award of the American Heart Association and in 2010, the Walter M. Booker Community Service Award of the Association of Black Cardiologists, of which he is past Chair and Chief Science Officer. He has been recognized by the Congressional Black Caucus Health Trust with an award for journalism, as well as the Charles Drew award for medical excellence in conjunction with the National Minority Quality Foundation. In 2015, Dr. Ferdinand was inducted into the Association of University Cardiologists.

Professor of Medicine at the Tulane University School of Medicine (New Orleans). Hypertension specialist certified by the American Society of Hypertension. Conducted numerous cardiovascular disease / hypertension clinical trials especially in racial and ethnic minorities.

Professor Frans Leenen, MD, PhD, FRCPC, FAHA, is the Director of the Hypertension Clinical and Research Program at the University of Ottawa Heart Institute. He is also Professor of Medicine and Pharmacology in the Department of Medicine and the Department of Cellular and Molecular Medicine at the University of Ottawa. He is an internationally recognised specialist in the study of the sympathetic nervous system and his research focuses on the role of brain mechanisms in hypertension and congestive heart failure and how these can be inhibited by drug therapy. He was one of the lead trial investigators for ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the largest study ever conducted in people suffering from hypertension, with more than 42,000 volunteers participating in 600 centres throughout Canada and the United States. He has authored more than 300 scientific publications, many of which have appeared in prestigious journals.

Director of the Hypertension program at the University of Ottawa Heart Institute. Professor of Medicine and Pharmacology at the University of Ottawa. His research focuses on the role of brain mechanisms in hypertension and congestive heart failure.

PRESS RELEASES